(Press-News.org) New York, September 27, 2013 -- Clinical trial design for new cancer therapies has historically been focused on the tissue of origin of a tumor, but a paper from researchers at Memorial Sloan-Kettering Cancer Center published on September 26 in Nature Genetics supports a new approach: one based on the genomic signature of a tumor rather than the tissue of origin in the body.
It is well known that the emergence of cancer is a multi-step process, but because of the efforts of The Cancer Genome Atlas (TCGA), funded by the US National Institutes of Health, and other large-scale cancer genomics efforts, for the first time this process can be viewed in exquisite molecular detail, mapping mutations and other molecular events affecting any of the 20,000 genes in a human cell.
Now, two major hypotheses have been confirmed from the genomic analysis of more than 3000 samples from 12 different tumor types: a limited number of specific genetic events appear to cause most tumor subtypes and tumors can be grouped by the oncogenic signatures they contain, no matter what the tissue of origin. That these oncogenic signatures are largely independent of the particular tissue in which the cancer arises indicates that certain drug combinations may be beneficial for select patients with different types of cancer.
"In future clinical trials, we envision that patients with a certain type of endometrial cancer, for example, may be enrolled in the same trial as patients with a subtype of colorectal cancer, and that patient selection for clinical trials can be guided by cancer genomics profiling in the clinic," stated Chris Sander, one of the principal investigators of Memorial Sloan-Kettering's Genome Data Analysis Center. "This work is intended to help in the design of such trials and the development of more-personalized cancer therapies."
The ability to reveal sets of cancer-causing events in molecular detail is based on three major technical and scientific developments in the last decade. New high-throughput genomic technologies and lower operating costs have enabled the collection of genetic data from many thousands of tumors. The experience and knowledge accumulated in cancer genomics in many laboratories has taught us which of the many molecular alterations in cancer are likely to contribute to oncogenesis. Linking data and knowledge, new algorithms and methods for large data analysis in the field of computational biology provide the ability to find the proverbial needles in the haystack: to derive cancer-causing molecular genetic signatures and link them to tumor subtypes and potential therapies on the background of extremely high levels of informational noise.
The Memorial Sloan-Kettering team and their colleagues in TCGA and the International Cancer Genome Consortium plan to expand these comprehensive analyses to tens of thousands of tumor samples. A glimpse of the molecular tumor landscape in more than 13,000 tumor samples is already accessible in the cBioPortal for Cancer Genomics at http://www.cbioportal.org.
Principal authors on the study are Giovanni Ciriello, Nikolaus Schultz, and Chris Sander of the Computational Biology Center at Memorial Sloan-Kettering.
The current research was supported in part by the National Cancer Institute under award number U24 CA143840.
###About Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private cancer center with more than 125 years devoted to exceptional patient care, innovative research, and outstanding educational programs. We are one of 41 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment.
The close collaboration between our physicians and scientists enables us to provide patients with the best care available as we work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan-Kettering has an impact on cancer treatment and biomedical research around the world. For more information, go to http://www.mskcc.org.
Oncogenic signatures mapped in TCGA a guide for the development of personalized therapy
2013-09-27
ELSE PRESS RELEASES FROM THIS DATE:
Setting blurred images in motion improves perception
2013-09-27
Philadelphia, Pa. (September 26, 2013) - Blurred images that are unidentifiable as still pictures become understandable once the images are set in motion. That's because of a phenomenon called "optic flow"—which may be especially relevant as a source of visual information in people with low vision, reports a study 'With an Eye to Low Vision: Optic Flow Enables Perception Despite Image Blur' (published online ahead of print, September 3, 2013) in the October issue of Optometry and Vision Science official journal of the American Academy of Optometry. The journal is published ...
Study examines health of kidney donors
2013-09-27
Washington, DC (September 26, 2013) — The short-term risks associated with kidney donation are relatively modest, but because many donors have additional medical conditions, it is important to evaluate their ongoing health. That's the conclusion of a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).
In more than a third of kidney transplantations performed in the United States, the transplanted organs come from live donors. Research suggests that there are minimal health consequences for donors, but only a few ...
NASA Mars rover Curiosity finds water in first sample of planet surface
2013-09-27
Troy, N.Y. – The first scoop of soil analyzed by the analytical suite in the belly of NASA's Curiosity rover reveals that fine materials on the surface of the planet contain several percent water by weight. The results were published today in Science as one article in a five-paper special section on the Curiosity mission. Rensselaer Polytechnic Institute Dean of Science Laurie Leshin is the study's lead author.
"One of the most exciting results from this very first solid sample ingested by Curiosity is the high percentage of water in the soil," said Leshin. "About 2 ...
Wildlife face 'Armageddon' as forests shrink
2013-09-27
Singapore, 27 September 2013 – Species living in rainforest fragments could be far more likely to disappear than was previously thought, says an international team of scientists.
In a study spanning two decades, the researchers witnessed the near-complete extinction of native small mammals on forest islands created by a large hydroelectric reservoir in Thailand.
"It was like ecological Armageddon," said Luke Gibson from the National University of Singapore, who led the study. "Nobody imagined we'd see such catastrophic local extinctions."
The study, just published ...
Pan-cancer studies find common patterns shared by different tumor types
2013-09-27
Cancer encompasses a complex group of diseases traditionally defined by where in the body it originates, as in lung cancer or colon cancer. This framework for studying and treating cancer has made sense for generations, but molecular analysis now shows that cancers of different organs have many shared features, while cancers from the same organ or tissue are often quite distinct.
The Pan-Cancer Initiative, a major effort to analyze the molecular aberrations in cancer cells across a range of tumor types, has yielded an abundance of new findings reported in 18 forthcoming ...
How can supply of penicillin be an issue in any country in 2013?
2013-09-27
Benzathine penicillin G (BPG) is the most essential antibiotic for the treatment and prevention of group A streptococcal infections associated with rheumatic fever and rheumatic heart disease. Yet while some countries such as South Africa and Brazil have stable supplies, most countries with a high RHD burden often suffer interruptions in supply and also have quality control issues. The problems around supply of this drug are discussed in one of the papers of the RHD special issue of Global Heart, the journal of the World Heart Federation. The paper is by Dr Rosemary Wyber, ...
Rheumatic heart disease: A new era of pushing for global control as World Heart Day approaches
2013-09-27
As this year's World Heart Day approaches (Sunday September 29), focus is returning to a neglected and entirely preventable heart disease that largely affects the world's youngest and poorest populations: rheumatic heart disease (RHD). To highlight this long-neglected condition, Global Heart, the journal of The World Heart Federation (WHF) is publishing a special issue dedicated to RHD.
The World Heart Federation views the publication of the special issue of Global Heart as a vital step in its target of reducing global RHD deaths in under 25s by 25% by 2025. Reducing ...
Increasing awareness that untreated sore throat can lead to rheumatic heart disease is a huge part of the battle
2013-09-27
Without a huge improvement in living conditions, a cure, or a vaccine, rheumatic heart disease (RHD) will continue to blight low-income and middle-income countries. Raising community awareness of the condition, emphasising that untreated sore throat caused by group A streptococcal (GAS) infection can lead to acute rheumatic fever (ARF)/RHD, is a huge part of the battle. The issues around advocacy and awareness are discussed in a paper in the RHD special issue of Global Heart, the journal of the World Heart Federation, written by Dr Liesl Zühlke, University of Cape Town ...
Current estimate of around quarter of a million deaths annually worldwide vastly underestimates true burden of rheumatic heart disease
2013-09-27
A paper in the RHD special issue of Global Heart, the journal of the World Heart Federation, analyses the burden of disease and suggests that numbers published to date (ranging from at least 233,000 deaths per year upwards) could be substantial underestimates for a variety of reasons, most commonly lack of high quality (or in some cases any) data from high-prevalence countries and regions. The paper is by Dr Liesl Zühlke, University of Cape Town and Red Cross War Memorial Children's Hospital, Cape Town, South Africa and Dr Andrew Steer, Centre for International Child Health ...
Diagnosing and treating sore throat (primary prevention) should be part of overall strategy to prevent rheumatic heart disease
2013-09-27
Diagnosing and treating sore (strep) throat (primary prevention) in children and adolescents to prevent such cases developing into acute rheumatic fever (ARF) and rheumatic heart disease (RHD) should be a cornerstone in any overall RHD strategy. The issues around primary prevention are discussed in one of the papers in the RHD special issue of Global Heart (the Journal of the World Heart Federation) by authors Dr Liesl Zühlke, University of Cape Town and Red Cross War Memorial Children's Hospital, Cape Town, South Africa, and Dr Ganesan Karthikeyan, All India Institute ...